GSK, J&J and Pfizer vie for $10B RSV vaccine market, with Bavarian Nordic and Moderna hot on their trail

Driving the fight against this virus, in a field potentially worth up to $10 billion annually by 2030, are GlaxoSmithKline, J&J, and Pfizer, all of which will intensely compete for market share in the coming years, potentially as early as the end of 2023, according to a new report from SVB Leerink.